Vaxxas’ Post

Want to know more about our Partnerships & Access track? Read below! As the landscape of global health continues to evolve, the role of strategic partnerships in vaccine development has never been more crucial. At the forefront of these discussions is this track which will delve into the most pressing issues and innovative strategies for fostering successful collaborations and shaping the future of vaccine accessibility and innovation. The Track will delve into: 🔹 Evolving trends in Europe's vaccine pipeline and new areas of focus 🔹Innovations in vaccine delivery 🔹Navigating government funding and non-diluted strategies for biotechs and biopharmas ➡️ Swipe to see the keynote panel that will discuss in more detail! 🎟️The congress awaits you! https://buff.ly/4dEnLa3 📆Pre-Congress Workshops | 28 October 2024 📍Catalonia Barcelona Plaza 📆Main Congress | 29 – 31 October 2024 📍Fira de Barcelona Montjuic #WVCEU #VaccineDevelopment #VaccineInnovation #HealthcareInnovation #Vaccines

#LabConnect #LivesDependOnIt #ClinicalTrials #SampleManagement #VaccineTrials When it comes to clinical trials, Patients Can't Wait. Vaccine studies can have a significant impact on supporting healthier communities around the world. However, they are often required to be executed swiftly and across multiple regions of the world. Through our global central lab services, #LabConnect successfully manages these challenges with expert clinical, operational, and analytical support to ensure the timely execution of your vaccine trial. #LabConnect – Lives Depend on it. ⭐ Get the Top Takeaways from our webinar “Clinical Sample Management: Expecting the Unexpected – How to Avoid Losing a Sample.“ ⭐https://lnkd.in/e2yp-v7d Learn more and explore how we can partner together to accelerate the development of new medicines.

When it comes to clinical trials, Patients Can't Wait. Vaccine studies can have a significant impact on supporting healthier communities around the world. However, they are often required to be executed swiftly and across multiple regions of the world. Through our global central lab services, LabConnect successfully manages these challenges with expert clinical, operational, and analytical support to ensure the timely execution of your vaccine trial. LabConnect – Lives Depend on it. ⭐ Get the Top Takeaways from our webinar “Clinical Sample Management: Expecting the Unexpected – How to Avoid Losing a Sample.“ ⭐   = >  https://lnkd.in/e2yp-v7d Learn more and explore how we can partner together to accelerate the development of new medicines. #LabConnect #LivesDependOnIt #ClinicalTrials #SampleManagement #VaccineTrials

Check out the National Press Foundation's first #webinar of 2024, "What You Need to Know About #COVID Antivirals," on January 11 from 11 a.m - 12 pm ET. #journalismtraining #healthreporting #COVID19 #antivirals

The stark disparities in vaccine distribution during the COVID-19 pandemic were heartbreaking and unsustainable. While rich countries in the north benefited from prompt vaccine availability, those in the Global South were left behind. The need for a new, reformed, regionally oriented approach to sustainable vaccine production as a path to equitable access was obvious. On this background, the Regionalized Vaccine Manufacturing Collaborative (RVMC) was established in 2022, co-chaired by CEPI with the U.S. National Academy of Medicine and the World Economic Forum. As of February 2024, the Collaborative enters a new operative phase with its own secretariat hosted by CEPI to support the goals and needs of regions, countries and corporations. Dr. Frederik Kristensen has stepped down from his role as Deputy CEO of CEPI to take on the job of Managing Director of the Collaboration. In this new blog, Dr Kristensen outlines where regionalized manufacturing progress has been made, how the RVMC seeks to further bolster these global efforts, and his imminent plans as he takes the helm of this Collaborative. Learn more ⬇️ https://lnkd.in/eKUtwKdE

VAC4EU is hosting another Journal Club appointment this month. Don’t forget to register!    🗓 Date: 28 June 15:00 CET  🗣 Presenter: Jungyeon (Yeon) Choi, PhD candidate at Universitair Medisch Centrum Utrecht  🔬 Topic: "A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases" (Schultze et al, 2024)  🔗 Registration: https://lnkd.in/e8mUCKrE   👉 Check out the paper: https://lnkd.in/edzF98RH   The Journal Club is a monthly appointment for members of VAC4EU and the wider scientific community. It exists for people with a common passion and curiosity for vaccine research. It is not a time to speak about work or deadlines, but rather a fun place to share open questions, doubts and progress in our understanding of interesting topics, owing to the interaction with one another. It is a place where we are not afraid that our questions are too naive.    During a VAC4EU Journal Club appointment, a speaker presents a published paper of their choice. The paper may cover any topic related to vaccine research, from methodological issues, to results of relevance, to curious findings. The speaker then has the opportunity to better understand a paper through critical discussion with the audience. The conversation is highly interactive, open, and informal! If you are interested in subscribing to the Journal Club mailing list, please reach out to the VAC4EU Secretariat at secretariat@vac4eu.org.    #VAC4EUjournalclub #scientificfun #targettrialemulation 

The Rapid Rise of the Global Vaccine Industry: A Call for Collaborative Action 🌍💉 The COVID-19 pandemic has highlighted the critical importance of a robust and adaptable global vaccine industry. Over the past few years, we have witnessed an unprecedented pace of vaccine development and deployment, with multiple effective vaccines brought to market in record time. This rapid progress is a testament to the ingenuity, dedication, and collaborative spirit of the scientific community worldwide. 🤝 However, to ensure equitable access and continued innovation, we must build upon this momentum through deeper international cooperation. Key considerations: - Accelerating R&D for emerging infectious diseases through data-sharing and joint research initiatives 🔬 - Streamlining regulatory approval processes to facilitate global distribution 📜 - Expanding manufacturing capacity and diversifying supply chains to meet worldwide demand 🏭 - Implementing mechanisms for fair and affordable access, especially for underserved regions 💸 By working together across borders, sectors, and disciplines, the global vaccine industry can continue to save lives and strengthen our collective resilience. 💪 The time is now to capitalize on this pivotal moment and shape a healthier, more secure future for all. Who's ready to join the charge? 🙋♀️🙋♂️ #VaccineIndustry #GlobalHealth #Collaboration

Exciting News! The 24th DCVMN Annual General Meeting report is now published! We are thrilled to share the comprehensive report from our recent Annual General Meeting, where industry leaders, innovators, and experts gathered to discuss and shape the future of vaccine development and manufacturing. The report highlights key insights, advancements, and collaborative efforts within the vaccine industry. Some of the standout topics include: 🔸 Innovations in vaccine technology 🔹 Strengthening partnerships across the sector 🔸 Strategies for improving global vaccine accessibility 🔹 Enhancing regulatory frameworks The AGM is a testament to our collective dedication to improving public health worldwide. A special thanks to all our members, partners, and speakers who contributed to the success of this event. We invite you to read the full report to learn more about the significant strides we are making in the field. Your engagement and support are vital as we continue to drive progress in vaccine development. 👉 https://lnkd.in/e5xZT9Aq #Vaccines #PublicHealth #DCVMN #AnnualGeneralMeeting #Innovation #GlobalHealth

Great news! 🚀🌐 💉 Our new publication on the Evaluation of Vaccine Immunogenicity—Correlates to Real-World Protection in Influenza has been published in a Viruses prestigious journal of virology. We had the privilege of collaborating with excellent colleagues on this paper. Recent events have underscored that despite decades of studying vaccine immunogenicity and efforts towards finding correlates of protection, evaluating real-world vaccine efficacy, and establishing meaningful licensing criteria still pose a significant challenge. In this paper, we review all aspects of influenza vaccine immunogenicity, including animal and human challenge studies, humoral and cellular immunity parameters, and their potential correlation with real-life protection from disease. 👉 Please visit the Fluart Innovative Vaccines website to read our new publication and join the discussion! 👉 https://t.ly/_5EDO #influenza #vaccine #immunity #antibody #lymphocyte #fluart #publication #cdmo #manufacturer

ICYMI living in an underground bunker since 2020, the vaccine market is hot hot hotter than ever. In pursuit of being the first to market, vaccine study startup can feel like a game of "Name that Tune", especially when it comes to data collection. I can deploy that solution in 6 weeks; I can deploy it in 4 weeks! But when it comes to electronic data collection, faster isn't always better. As someone with years of experience in eCOA for vaccine trials, I've seen firsthand the impact of rushed delivery. While it may seem like the shortest possible timeline provides the biggest value to sponsors, it often creates quality issues down the line. These issues impact everyone involved in the trial, from participants to site and monitoring teams to vendors, and the sponsor team themselves. That's why it's important to take a more nuanced approach to evaluating technology implementation in trials. By analyzing a broader range of implementation metrics and developing a coherent story, we can justify more methodical and measured development and deployment. And by training staff in every client-facing function on how to message this value proposition consistently, we challenge the dogma that faster is always better. So let's take the time to get it right and prioritize quality over speed. Because in the long run, that's what will truly make a difference in the participant experience, the data quality, and speed to market. #VaccineTrials #ClinicalResearch #eCOA #QualityOverSpeed